Animal study reveals that instant tartary buckwheat tea powder improves lipid profiles in hyperlipidemic mice, indicating therapeutic potential against dyslipidemia.
To develop hypolipidemic instant tartary buckwheat tea powder (TBP), Box-Behnken response surface methodology was used to optimize flavonoid extraction, and ion mobility spectrometry tracked volatile variations during processing, with spray drying selected as the optimal drying technique. The optimal extraction parameters were 43 °C, 44 min, solid-liquid ratio 1:28 g/mL, yielding 3.32% total flavonoids. In vivo experiments showed that after 56 days of administration, the serum high-density lipoprotein cholesterol (HDL-C) level of hyperlipidemic ICR mice in the high-dose TBP group was 5.23 mmol/L, significantly higher than that in the model group ( p < 0.05). Compared with the model group, the high-dose TBP significantly reduced the levels of low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and total cholesterol (T-CHO) ( p < 0.01), simultaneously alleviating pathological damage to hepatocytes and adipocytes. Mechanistically, network pharmacology identified 137 core targets (e.g., AKT1, PPARG) and 20 essential signaling pathways (e.g., Lipid and atherosclerosis), revealing that the involved hypolipidemic effects of TBP are primarily mediated by key active components including rutin, quercetin, kaempferol, etc. This study providesa robustt theoretical basis and practical insights for the development of novel natural hypolipidemic agents.
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: